These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25838513)

  • 1. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
    Dejgaard TF; Knop FK; Tarnow L; Frandsen CS; Hansen TS; Almdal T; Holst JJ; Madsbad S; Andersen HU
    BMJ Open; 2015 Apr; 5(4):e007791. PubMed ID: 25838513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial.
    Johansen NJ; Dejgaard TF; Lund A; Vilsbøll T; Andersen HU; Knop FK
    BMJ Open; 2018 Jun; 8(6):e021861. PubMed ID: 29950475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
    Dejgaard TF; Schmidt S; Frandsen CS; Vistisen D; Madsbad S; Andersen HU; Nørgaard K
    Diabetes Obes Metab; 2020 Apr; 22(4):492-500. PubMed ID: 31696598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.
    Anholm C; Kumarathurai P; Klit MS; Kristiansen OP; Nielsen OW; Ladelund S; Madsbad S; Sajadieh A; Haugaard SB;
    BMJ Open; 2014 Jul; 4(7):e005942. PubMed ID: 25031198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
    Frandsen CS; Dejgaard TF; Andersen HU; Holst JJ; Hartmann B; Thorsteinsson B; Madsbad S
    Diabetes Obes Metab; 2017 Jun; 19(6):773-782. PubMed ID: 27868372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
    Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
    Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
    Pieber TR; Deller S; Korsatko S; Jensen L; Christiansen E; Madsen J; Heller SR
    Diabetes Obes Metab; 2015 Aug; 17(8):742-50. PubMed ID: 25855340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial.
    Larsen EL; Cejvanovic V; Kjær LK; Vilsbøll T; Knop FK; Rungby J; Poulsen HE
    BMJ Open; 2017 May; 7(5):e014728. PubMed ID: 28490557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
    Gudbergsen H; Henriksen M; Wæhrens EE; Overgaard A; Bliddal H; Christensen R; Boesen MP; Knop FKK; Astrup A; Rasmussen MU; Bartholdy C; Daugaard C; Bartels EM; Ellegaard K; Heitmann BL; Kristensen LE
    BMJ Open; 2019 May; 9(5):e024065. PubMed ID: 31061017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.
    Kuhadiya ND; Dhindsa S; Ghanim H; Mehta A; Makdissi A; Batra M; Sandhu S; Hejna J; Green K; Bellini N; Yang M; Chaudhuri A; Dandona P
    Diabetes Care; 2016 Jun; 39(6):1027-35. PubMed ID: 27208343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial.
    Foghsgaard S; Vedtofte L; Mathiesen ER; Svare JA; Gluud LL; Holst JJ; Damm P; Knop FK; Vilsbøll T
    BMJ Open; 2013 Oct; 3(10):e003834. PubMed ID: 24176797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes.
    Kuhadiya ND; Prohaska B; Ghanim H; Dandona P
    Diabetes Obes Metab; 2019 Apr; 21(4):1054-1057. PubMed ID: 30536789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial).
    Lind M; Hirsch IB; Tuomilehto J; Dahlqvist S; Torffvit O; Pehrsson NG
    Prim Care Diabetes; 2015 Feb; 9(1):15-22. PubMed ID: 25175385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study).
    Jorsal A; Wiggers H; Holmager P; Nilsson B; Nielsen R; Boesgaard TW; Kumme A; Møller JE; Videbæk L; Kistorp C; Gustafsson I; Tarnow L; Flyvbjerg A
    BMJ Open; 2014 May; 4(5):e004885. PubMed ID: 24844271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
    Dubé MC; D'Amours M; Weisnagel SJ
    Diabetes Obes Metab; 2018 Jan; 20(1):178-184. PubMed ID: 28722271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Pieters IC; Cahen DL; Diamant M; van Raalte DH
    BMJ Open; 2015 Nov; 5(11):e009579. PubMed ID: 26586327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial.
    Lane W; Weinrib S; Rappaport J; Hale C
    Diabetes Obes Metab; 2014 Sep; 16(9):827-32. PubMed ID: 24589127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.
    Larsen JR; Vedtofte L; Holst JJ; Oturai P; Kjær A; Correll CU; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2014 Mar; 4(3):e004227. PubMed ID: 24667381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus.
    Mader JK; Jensen L; Ingwersen SH; Christiansen E; Heller S; Pieber TR
    Clin Pharmacokinet; 2016 Nov; 55(11):1457-1463. PubMed ID: 27282158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.